Silvia Priori, M.D., Ph.D. Delivers the William Harvey Lecture on Basic Science
CAMBRIDGE, MASS. – [October 2, 2018] – The European Society of Cardiology Congress holds four specialized lectures each year and selects four renowned scientists who are seen by their peers as leading experts in their corresponding fields. The William Harvey Lecture on Basic Science is a noteworthy accolade and recognizes a member of the scientific […]
Cardurion Pharmaceuticals Announces Initiation of Phase 1 Study of CRD-733, a PDE-9 Inhibitor in Development for the Treatment of Heart Failure
CAMBRIDGE, MASS. – [September 20, 2018] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) for CRD-733, a Phosphodiesterase-9 (PDE-9) inhibitor in development to improve cardiac function […]
Cardurion Pharmaceuticals Appoints Jeb Keiper to Its Board of Directors
CAMBRIDGE, MASS. – [August 16, 2018] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of industry leader, Jeb Keiper, as an independent member of its Board of Directors. Mr. Keiper joins founder Michael Mendelsohn, M.D., Ken Novack, Ed Mascioli, M.D. […]
Cardurion Pharmaceuticals Appoints Rebecca Frey as Chief Operating Officer
CAMBRIDGE, MASS. – [July 24, 2018] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced that it has expanded its leadership team with the addition of chief operating officer, Rebecca V. Frey, Pharm.D. “The expansion of our leadership team will not only […]
Cardurion Pharmaceuticals Announces Formation of Scientific and Clinical Advisory Board
CAMBRIDGE, MASS. – [June 26, 2018] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced that it has assembled world-class Scientific and Clinical Advisory Boards. “Cardiovascular disease is the leading cause of death in both men and women and accounts for one-third of […]
Cardurion Pharmaceuticals Licenses Clinical Stage Heart Failure Candidate from Astellas
Company expanding pipeline of novel treatments for cardiovascular disease CAMBRIDGE, MASS. – [April 16, 2018] – Cardurion Pharmaceuticals, a biotechnology company focused on the development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced it has entered an exclusive licensing agreement with Astellas to develop and commercialize CRD-733, a PDE-9 inhibitor with […]
Takeda and Cardurion Pharmaceuticals Launch Cardiovascular Development Partnership
Collaboration to develop novel, next-generation therapeutics to treat heart disease Osaka, Japan and Cambridge, Mass., – 2 August 2017 – Takeda Pharmaceutical Company Limited (TSE: 4502) and Cardurion Pharmaceuticals today announced the creation of a new cardiovascular development partnership. Cardurion, a recently launched Boston-area based biotechnology company, is focused on the development of novel, next-generation […]
